Emerging medical therapies for NAFLD and for alcoholic hepatitis.
Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) are currently the two most common liver diseases in the world. Alcoholic hepatitis (AH), a unique clinical syndrome among ALD patients has high short-term mortality. Apart from controlling the risk factor for individual respective disease, there are no Food and Drug Administration (FDA) approved medical therapies for these diseases.
Wong VW and Singal AK. Transl Gastroenterol Hepatol. 2019 Jul 19;4:53